MammaPrint analyzes the 70 most important genes associated with breast cancer recurrence to classify each breast cancer patient into “Low Risk” or “High Risk” of developing metastases within the first 10 years after diagnosis—without the ambiguity associated with “intermediate” scores found in some other tests.
The clarity that MammaPrint delivers helps patients and physicians make informed, confident treatment management decisions.
MammaPrint is FDA-cleared (US) for women of all ages. The device is also CE marked allowing for use in the European Union.
The test is validated by peer-reviewed data and supported by the highest level of clinical evidence from a landmark randomized,* prospective,† phase III‡ clinical trial known as MINDACT.
MammaPrint is included in numerous clinical practice guidelines developed by world-recognized cancer care organizations. Clinical guidelines are evidence-based recommendations for healthcare professionals involved in the management of patients.
Guidelines aim to improve the quality of care and services based on the most up to date peer-reviewed evidence. For example, MammaPrint is the only test of its kind endorsed by the American Society of Clinical Oncology for lymph node-positive patients.
2 Wuerstlein R, et al. Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIMe Decision Impact Study. Poster presented at San Antonio Breast Cancer Symposium. December 2016; San Antonio, Texas